Psyence BioMed forms Texas Ibogaine Research Corp to advance U.S. ibogaine development

PUBT · 3d ago
Psyence BioMed forms Texas Ibogaine Research Corp to advance U.S. ibogaine development
  • Psyence BioMed formed Texas Ibogaine Research Corporation as a new Texas-based unit to run its U.S. ibogaine development.
  • The entity is intended to centralize pharmaceutical-grade supply, manufacturing planning, regulatory engagement, potential clinical development, within one U.S. vehicle.
  • TIRC is positioned to hold U.S. rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to definitive licensing agreements.
  • Jody Aufrichtig will lead TIRC as CEO; Dr. John Thorne was appointed project lead.
  • Next steps include finalizing licensing, advancing regulatory work, preparing manufacturing and clinical plans for a potential U.S. program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-099451), on September 14, 2026, and is solely responsible for the information contained therein.